Notice of Intent to Award a Sole Source Contract to Biolog
Inactive on SAM.gov — responses were due 9 Jul 2026 · No Set aside used · Food and Drug Administration (FDA), HHS · Laurel, MD · NAICS 334516 · Solicitation FDA-133991
Following NAICS 334516? Get new solicitations in it by email as they post — no account needed.
SAM.gov marked this notice inactive — responses were due 09 July 2026.
No award notice on SAM.gov yet. Not every award is posted there, so this does not mean it went unawarded.
Email me when the award is announced. One email, when SAM.gov posts the award notice. Not every award is posted there; if none appears within six months we'll tell you and stop. No account needed.
This one has closed. We'll email you when new NAICS 334516 (Analytical Laboratory Instrument Manufacturing) solicitations post — the first email lists what is open right now, then at most once a week, only when something new posts. No account needed; unsubscribe in a click.
Description
Notice of Intent to Award a Sole Source Contract to Biolog (FDA-133991) The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price commercial Purchase Order (PO) to Biolog Inc. 21124 Cabot Blvd., Hayward, CA 94545 for the Purchase of Integrated Dual-Mode Microbial Phenotypic Analysis System in accordance with the authority under FAR RFO Part 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. The NAICS Code for this action is 334516 Analytical Laboratory Instrument Manufacturing industry. This acquisition is being conducted using simplified acquisition procedures in accordance with FAR RFO Part 12 for the acquisition of commercial products and commercial services. Biolog is the only manufacturer of the Integrated Dual-Mode Microbial Phenotypic Analysis System that is uniquely capable of integrating with the FDA's existing maintaining compatibility with phenotypic microarray plates and validated workflows. Market research did not identify any alternative analyzers capable of providing an integrated platform that simultaneously measures redox respiration and optical density growth kinetics, compatibility with proprietary phenotypic microarray plates currently in use. This notice is not a request for competitive quotes. Any other firms desiring consideration must fully identify their interest and capability of meeting the requirements by submitting a capability statement to Janice Heard at janice.heard@fda.hhs.gov no later than July 09, 2026. Any response shall undergo review to determine if it can meet the requirements. A determination by the Government not to compete this proposed requirement based upon a response to this notice is solely within the discretion of the Government.
Go deeper on this solicitation
FedSift reads the full solicitation package — every attachment — and pre-extracts the compliance matrix, evaluation factors, key risks, win themes and deal-breakers, each with a verbatim quote and the exact PDF page it came from. It scores the opportunity against your company profile, tells you whether to bid as prime or sub, and ranks teaming partners who could close your gaps.
Source: this notice on SAM.gov. FedSift republishes public federal procurement data and is not affiliated with the U.S. Government. Always confirm dates and requirements against SAM.gov before responding.
